Earnings summaries and quarterly performance for Rafael Holdings.
Research analysts covering Rafael Holdings.
Recent press releases and 8-K filings for RFL.
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
RFL
Earnings
M&A
New Projects/Investments
- Rafael Holdings, Inc. reported a net loss attributable to Rafael Holdings of $9.8 million, or $0.19 per share, for the first quarter fiscal year 2026 ended October 31, 2025.
- This net loss increased from $9.0 million, or $0.37 per share, in the year-ago period, primarily due to the consolidation of Cyclo Therapeutic’s expenses following its acquisition in March 2025.
- As of October 31, 2025, the company held cash and cash equivalents of $45.5 million.
- Research and development expenses rose to $7.5 million for the quarter, compared to $1.3 million in the prior year period, mainly due to the inclusion of Cyclo's spending.
- The Data Monitoring Committee (DMC) recommended continuing the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 after reviewing safety and efficacy data at 48 weeks.
Dec 11, 2025, 9:19 PM
Rafael Holdings Reports Q1 Fiscal 2026 Results
RFL
Earnings
M&A
New Projects/Investments
- Rafael Holdings reported a net loss attributable to Rafael Holdings of $9.8 million, or $0.19 per share, for the first quarter fiscal year 2026 ended October 31, 2025.
- As of October 31, 2025, the company had cash and cash equivalents of $45.5 million.
- Research and development expenses increased to $7.5 million for the three months ended October 31, 2025, compared to $1.3 million in the year-ago period, primarily due to the inclusion of spending at Cyclo following its acquisition in March 2025.
- The Data Monitoring Committee recommended continuing the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 after reviewing prespecified safety and efficacy data at 48 weeks.
Dec 11, 2025, 9:01 PM
Rafael Holdings Reports Q4 and Full Year Fiscal 2025 Financial Results
RFL
Earnings
Management Change
New Projects/Investments
- Rafael Holdings reported a net loss attributable to Rafael Holdings of $12.1 million, or $0.28 per share, for the fourth quarter of fiscal year 2025, and a net loss of $30.5 million, or $1.04 per share, for the full fiscal year 2025.
- As of July 31, 2025, the company held $52.8 million in cash and cash equivalents, following the closing of a $25 million rights offering in June 2025.
- Research and development expenses significantly increased to $7.5 million for the three months ended July 31, 2025, and $12.8 million for the twelve months ended July 31, 2025, primarily due to the consolidation of Cyclo Therapeutics, Cornerstone, and Day Three.
- The TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ is continuing at the recommendation of the Data Monitoring Committee.
- Joshua Fine was elected Chief Operating Officer on August 4, 2025, and Alan Grayson was added to the Board of Directors, with Markus Sieger named Chair of the Audit Committee.
Oct 29, 2025, 8:36 PM
Rafael Holdings Reports Q4 and FY 2025 Financial Results
RFL
Earnings
New Projects/Investments
Management Change
- Rafael Holdings reported a net loss attributable to Rafael Holdings of $12.1 million, or $0.28 per share, for the fourth quarter ended July 31, 2025, and a net loss of $30.5 million, or $1.04 per share, for the full fiscal year 2025.
- As of July 31, 2025, the company had $52.8 million in cash and cash equivalents.
- The company closed a $25 million rights offering in June 2025, which included a $21.0 million backstop commitment from the Jonas family.
- The Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ is continuing at the recommendation of the Data Monitoring Committee (DMC).
Oct 29, 2025, 8:24 PM
Rafael Holdings: Niemann-Pick Disease Type C Market Insights
RFL
Product Launch
M&A
- The Niemann-Pick disease type C market was valued at USD 60 million in 2024 and is projected to grow at a CAGR of 14.8% during the forecast period (2025–2034).
- Rafael Holdings completed a merger with Cyclo Therapeutics in March 2025, with Cyclo Therapeutics actively developing Trappsol Cyclo, a key emerging therapy for Niemann-Pick disease type C.
- The market's growth is driven by the emergence of novel therapies and rising prevalence, with approximately 1000 diagnosed prevalent cases in the 7MM in 2024.
- Recent regulatory milestones include the FDA approval of MIPLYFFA in September 2024 and a positive opinion for marketing authorization for AQNEURSA in July 2025 for NPC treatment.
Oct 29, 2025, 5:00 PM
Rafael Holdings Announces Clinical Trial Progress and FDA Approval
RFL
Product Launch
New Projects/Investments
- Rafael Holdings, Inc. (RFL) announced that an independent Data Monitoring Committee recommended the continuation of its Trappsol® Cyclo Phase 3 clinical trial for Niemann-Pick Disease Type C1 (NPC1) following an interim analysis in June 2025. The final analysis is targeted for the first half of 2026, with potential regulatory submissions to the FDA and EMA by the end of 2026.
- As of April 30, 2025, the company reported a cash balance of approximately $62.8 million and stated it has sufficient capital to fund through multiple value-creating milestones.
- The global market for Niemann-Pick Disease is projected to exceed $920 million by 2033.
- Rafael Holdings received FDA approval in December 2024 for an all-in-one Endoscopic Carpal Tunnel Release system.
Oct 10, 2025, 1:47 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more